London (UK) and Rehovot (Israel). VIDAC PHARMA HOLDING PLC (SYM: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ). (www.vidacpharma.com) is happy to announce a listing of company shares in the Hamburg Stock Exchange.
Vidac Pharma is a clinical stage company exploiting a new paradigm in Anti-Cancer Drug Discovery by dissociating the enzymatic complex which causes hyper glycolysis in Cancer Cells known as the Nobel Prize winner Warburg Effect. Vidac Pharma is the first company to develop and patent new potent molecules for Cancer treatment based on this basic mechanism which is also used for diagnostic of cancer metastases (PET-Scan) but was reputed as “undruggable” until Vidac Pharma discoveries. Vidac Pharma is in Phase 2 with its proprietary molecules in two Skin Cancer pathologies, cSCC (AK) and CTCL and develops new molecules for solid tumors.
Vidac Pharma Holding Plc is the Holding Company of Vidac Pharma Ltd from the Weizmann Science Park in Rehovot, Israel.
The following information does not constitute a public offer to sell or a solicitation to submit an offer to buy or subscribe to shares of Vidac Pharma Holding PLC, but is for informational purposes only.
Vidac Pharma Holding PLC
Dr. Max Herzberg
20-22 Wenlock Road
London N1 7GU